association of coagulation activation with clinical complications in sickle cell disease协会的凝血激活镰状细胞病的临床并发症.pdf

Association of Coagulation Activation with Clinical Complications in Sickle Cell Disease 1 2 1 3 1 1¤ Kenneth I. Ataga *, Julia E. Brittain , Payal Desai , Ryan May , Susan Jones , John Delaney , Dell 1 4 1 Strayhorn , Alan Hinderliter , Nigel S. Key 1 Division of Hematology/Oncology, University of North Carolina, Chapel Hill, North Carolina, United States of America, 2 Department of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, United States of America, 3 Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina, United States of America, 4 Division of Cardiology, University of North Carolina, Chapel Hill, North Carolina, United States of America Abstract Background: The contribution of hypercoagulability to the pathophysiology of sickle cell disease (SCD) remains poorly defined. We sought to evaluate the association of markers of coagulation and platelet activation with specific clinical complications and laboratory variables in patients with SCD. Design and Methods: Plasma markers of coagulation activation (D-dimer and TAT), platelet activation (soluble CD40 ligand), microparticle-associated tissue factor (MPTF) procoagulant activity and other laboratory variables were obtained in a cohort of patients with SCD. Tricuspid regurgitant jet velocity was determined by Doppler echocardiography and the presence/history of clinical complications was ascertained at the time of evaluation, combined with a detailed review of the medical records. Results: No significant differences in the levels of D-dimer, TAT, solu